drugset / Trial / NCT06772246

A Study to Evaluate QTc Prolongation With Quizartinib in Healthy Subjects Under Rapid Acceleration of Heart Rate

NCT06772246

Phase 1 Completed 70 enrolled Daiichi Sankyo
NaSingle-groupOpen-labelTreatment

Summary

This study will evaluate the impact of rapid acceleration in the heart rate on the QT prolongation of quizartinib.

Timeline

Start
2024-10-24
Primary completion
2025-06-12
Completion
2025-06-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Quizartinib Small molecule 90 mg Oral

Indications

No indication recorded.